drugset / Trial / NCT01269450

Progesterone and Second Trimester Bleeding

NCT01269450

Terminated 128 enrolled HaEmek Medical Center, Israel
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Working hypothesis and aims: To investigate whether progesterone treatment affects the incidence of preterm labor compared to placebo, among women with 2nd trimester bleeding. The participants will be allocated through randomization to a study or control group. Women in the study group will receive micronized progesterone 200 mg (Utrogestan, company) with an intra-vaginal tablet once daily while the control group will receive placebo. Both women and medical staff will be blinded to group allocation. Treatment will commence on the day of inclusion to the study, but not before 16 weeks and will continue until 36 weeks gestation. Data will be collected after the conclusion of pregnancy regarding the maternal and neonatal outcome.

Timeline

Start
2011-03
Primary completion
2017-01
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Progesterone Other / unclassified 200 mg Other

Indications